ETFs Investing in Editas Medicine, Inc. Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold Editas Medicine, Inc. stocks, sorted by market value. It details various ETFs, including those from BlackRock, Vanguard, and Invesco, highlighting their management style, focus, expense ratio, assets under management (AUM), and performance metrics. The information aims to help investors identify ETFs with exposure to Editas Medicine, Inc. for diversified investment opportunities.
Editas Medicine (NASDAQ:EDIT) Trading 14.4% Higher - Here's What Happened
Editas Medicine (NASDAQ:EDIT) shares surged 14.4% to $3.30, with approximately 1.74 million shares traded. The company surpassed quarterly expectations, reporting an adjusted loss of $0.15 per share against an estimated $0.27 loss, and revenue of $11.89 million compared to a $2.85 million forecast. Analyst sentiment remains largely positive, holding a "Moderate Buy" consensus rating and an average price target of $5.50.
EDIT Initiates Coverage On Ladenburg Thalmann - Rating Set to Buy
Ladenburg Thalmann has initiated coverage on Editas Medicine (EDIT) with a Buy rating and a price target of $6.00, according to GuruFocus. Despite this positive analyst outlook, GuruFocus indicates that EDIT is currently overvalued by 23.5% with a GF Value of $2.30 compared to its current price of $2.84, and has a moderate GF Score of 58/100 due to strong momentum but poor profitability. Investors are advised to proceed with caution given the high price-to-sales ratio and mixed insider activity.
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH initiated coverage on Editas Medicine (NASDAQ:EDIT) with a "buy" rating and a $6.00 price target, representing a potential upside of over 111%. This follows Editas Medicine reporting quarterly revenue of $11.89 million and an adjusted loss of $0.15 per share, significantly exceeding analyst expectations. The company currently holds an average rating of "Moderate Buy" from analysts, with institutional investors owning a substantial 71.90% of the stock.
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP
GSA Capital Partners LLP has acquired a new stake of 367,147 shares in Editas Medicine, Inc. (NASDAQ:EDIT), valued at approximately $1.19 million, representing about 0.37% of the company. Other institutional investors have also increased their holdings, while company insiders have sold some shares. Editas Medicine, a clinical-stage biotechnology company, reported stronger-than-expected earnings for the last quarter and holds a "Moderate Buy" consensus rating from analysts with a target price of $5.40.
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts
Editas Medicine (NASDAQ:EDIT) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy, one a hold, and one a sell. The average 12-month price target is $5.40, significantly higher than its recent trading price of $2.82. The company, which focuses on CRISPR-based treatments, exceeded quarterly revenue and EPS estimates but remains unprofitable with a negative net margin.
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have disclosed a beneficial ownership of 5.8% in Editas Medicine, Inc. This stake, totaling 8,889,000 shares, is held by private investment funds managed by ADAR1 Capital Management. The filing indicates shared voting and dispositive power over these shares, with Mr. Schneeberger acting as a control person for the investment adviser.
Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN
Editas Medicine, Inc. reported a net loss of $18.2M and revenues of $11.9M for Q2 2026, with cash reserves sufficient until H2 2028. The company is advancing its EDIT-401 program by filing an Australian CTN to initiate a Phase 1/2 trial for HeFH in Australia and New Zealand, with topline data expected in 2027.
HC Wainwright Boosts Earnings Estimates for Editas Medicine
HC Wainwright has revised its earnings estimates for Editas Medicine, projecting narrower losses for fiscal years 2026 and 2027. Despite the improved forecasts, the gene-editing company is still expected to remain unprofitable through 2027. Editas Medicine recently surpassed analyst expectations for its quarterly earnings and revenue, while insider transactions show some selling activity from the CEO.
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold
Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional investors, including BlackRock, have significantly increased their holdings.
Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement
Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) using AI and is based on original content filed by Editas Medicine Inc. via EDGAR.
Editas Medicine, Inc. (EDIT) director reports no share or option holdings
A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this individual. Ellinor Patrick Thomas II is identified solely as a director, not as an officer or a ten percent owner.
Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000
Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, the director directly holds 103,400 derivative securities.
Editas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger
Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, and basic EPS loss decreased to US$0.15 from US$0.63. Despite this positive momentum, the article notes that funding risks and volatility remain concerns for the clinical-stage biotech.
Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary
Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate with a Phase 1/2 trial planned, and successful equity offering to fund operations into the second half of 2028. The company has also narrowed its R&D priorities and completed workforce reductions.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and durable LDL cholesterol reductions in non-human primates. Editas plans to submit a Clinical Trial Notification in Australia in August 2026 to initiate a phase I/II study for EDIT-401, with data updates expected in Q1 2027 and top-line results later in 2027.
Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the year.
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results
Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains unprofitable and its stock traded down 0.5% to $2.75. Analyst sentiment is mixed but leans positive, with a "Moderate Buy" rating and an average price target of $5.40.
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. Despite outperforming the market year-to-date, Editas currently holds a Zacks Rank
Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M
Editas Medicine reported a Q2 2026 net loss of $18.2 million, significantly trimmed from $53.2 million a year prior, and saw collaboration revenues increase to $11.9 million. The company's cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026, boosted by a May 2026 equity offering that raised $116.9 million in net proceeds. Editas Medicine expects this liquidity to fund operations for at least the next twelve months and is focusing resources on its EDIT-401 program for heterozygous familial hypercholesterolemia, with initial patient data anticipated in 2027.
Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan
Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, and was not a discretionary trade. Following the sale, Parison directly holds 14,292 shares of Editas Medicine common stock.
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine reported its Q2 2026 financial results and provided business updates, highlighting the advancement of its gene editing program, EDIT-401, for hyperlipidemia. The company
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine announced its second-quarter 2026 financial results, highlighting progress in its EDIT-401 program for hyperlipidemia, including plans for a Clinical Trial Notification submission in Australia and preclinical data showing significant reduction in atherogenic lipoproteins. The company also strengthened its capital position through a recent financing, extending its cash runway into the second half of 2028, and appointed Patrick T. Ellinor, M.D., Ph.D. to its Board of Directors.
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Editas Medicine has appointed Patrick T. Ellinor, M.D., Ph.D., a recognized leader in cardiovascular medicine and human genetics, to its Board of Directors. Dr. Ellinor brings extensive experience in scientific innovation, therapeutic discovery, and clinical leadership, which will be invaluable as Editas advances its EDIT-401 program and in vivo gene editing platform. Concurrently, Elliott Levy, M.D., will step down from the Board.
A cardiovascular leader joins Editas as a director steps down
Editas Medicine has appointed Dr. Patrick T. Ellinor, a renowned leader in cardiovascular medicine and human genetics, to its Board of Directors, effective August 6, 2026. Dr. Ellinor's expertise is expected to significantly contribute to the advancement of EDIT-401 for hyperlipidemia and the company's in vivo gene editing platform. Concurrently, Dr. Elliott Levy will be stepping down from his role as an independent director.
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday
Editas Medicine (EDIT) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.30 per share and $2.85 million in revenue. The company's previous quarter showed a narrower-than-expected loss but significantly missed revenue estimates, maintaining a deeply unprofitable status with a negative net margin of 281.59%. Despite insider selling, institutional investors hold a significant portion of the stock, and analysts have a "Moderate Buy" consensus with an average price target of $5.40.
Editas Medicine appoints Patrick Ellinor to board of directors
Editas Medicine has appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6. Dr. Ellinor brings extensive experience in human genetics and cardiovascular research from his roles at Mass General Brigham Heart and Vascular Institute and the Broad Institute. He will contribute to the company's efforts in advancing gene editing medicines, particularly for hyperlipidemia, as Elliott Levy, M.D., steps down from the board.
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Editas Medicine announced the appointment of Patrick T. Ellinor, M.D., Ph.D., a recognized leader in cardiovascular medicine and human genetics, to its Board of Directors, effective August 6, 2026. Dr. Ellinor's expertise in scientific innovation, therapeutic discovery, and clinical leadership will be invaluable as Editas advances its gene-editing programs, particularly EDIT-401 for hyperlipidemia. Concurrently, Elliott Levy, M.D., will step down from the Board.
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Editas Medicine has appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026. Dr. Ellinor, a recognized leader in cardiovascular medicine and human genetics, brings extensive experience in scientific innovation and therapeutic discovery, which will be invaluable as Editas advances its EDIT-401 program. Concurrently, Elliott Levy, M.D., will step down from the Board.
Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT
Renaissance Technologies LLC increased its stake in Editas Medicine, Inc. by 30.7% in the first quarter of 2026, acquiring an additional 932,382 shares to own a total of 3.97 million shares valued at $9.8 million. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 71.9% of the company. Despite mixed analyst ratings, with a "Moderate Buy" consensus and a $5.40 price target, the company reported an EPS beat but a revenue miss for the quarter, as it continues to develop CRISPR-based treatments.
Editas Medicine EVP, chief scientific officer, sells $13,157 in stock By Investing.com
Linda Burkly, EVP and Chief Scientific Officer of Editas Medicine (NASDAQ:EDIT), sold 4,928 shares totaling approximately $13,157 to cover tax obligations from vested restricted stock units. This non-discretionary sale occurred as the stock saw a 31% gain over six months, despite its high volatility. The company recently announced a $125 million stock offering, presented promising preclinical data for EDIT-401, and elected new directors.
Editas Medicine EVP, chief scientific officer, sells $13,157 in stock
Linda Burkly, EVP and Chief Scientific Officer at Editas Medicine (NASDAQ:EDIT), sold 4,928 shares of company stock for approximately $13,157 to cover tax withholding obligations. This transaction was part of a pre-arranged sales plan and not a discretionary trade. The sale occurred as Editas Medicine shares have gained about 31% in the last six months, though the stock remains volatile.
BlackRock (NYSE: BLK) discloses 4.97% beneficial stake in Editas Medicine (EDIT)
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.97% in Editas Medicine, Inc., totaling 8,355,588 shares. This filing indicates that BlackRock holds sole voting power over 8,226,483 shares and sole dispositive power over all 8,355,588 shares. The disclosure also states that no single underlying person or client of BlackRock has more than five percent of Editas Medicine's outstanding common shares.
Editas Medicine EVP, chief scientific officer, sells $13,157 in stock
Linda Burkly, EVP and Chief Scientific Officer at Editas Medicine (NASDAQ:EDIT), sold 4,928 shares totaling $13,157 to cover tax obligations from vested restricted stock units. This transaction was part of a pre-adopted automatic sales instruction plan, not a discretionary trade. The sale occurred as Editas Medicine's stock has seen a 31% gain over the past six months, despite concurrent recent news of a public offering and promising preclinical data for EDIT-401.
Editas Medicine (NASDAQ:EDIT) EVP Linda Burkly Sells 4,928 Shares of Stock
Editas Medicine EVP Linda Burkly sold 4,928 shares of the company's stock for approximately $13,158, reducing her holdings by 7.32%. The sale was part of a pre-arranged plan to cover tax obligations related to vested equity awards. The company recently reported better-than-estimated earnings per share but missed revenue expectations, with analysts maintaining a "Moderate Buy" rating with a consensus price target of $5.40.
Editas Medicine Inc (EDIT) Income Statement
This article provides the quarterly and annual income statement for Editas Medicine Inc (EDIT), allowing users to analyze its financial performance and operational efficiency. It presents data including total revenue, operating expenses, net income, and earnings per share across various fiscal quarters and years. The page also includes FAQs to help users interpret the financial data presented on TradingKey.com.
Editas Medicine, Inc. Revenue Breakdown – NASDAQ:EDIT
Editas Medicine, Inc. (NASDAQ: EDIT) generated $40.52 million USD in revenue last year, primarily from its Gene Editing Technology segment, an increase from $32.31 million USD the prior year. All of this revenue was attributed to the United States market. The article provides a high-level overview of the company's revenue performance.
EDIT|Editas Medicine Inc|Price:2.600|Chg%:-0.130
Editas Medicine Inc. (EDIT) has healthy fundamentals and significant growth potential, although its stock price is expected to trend down in the medium term. The company is currently fairly valued within the Biotechnology & Medical Research industry and shows very high institutional ownership. Analysts have rated it a "Buy" with a high price target of $5.66, despite recent weak stock market performance.
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis
Editas Medicine Inc (EDIT) has a current valuation score of 7.00, placing it 277th out of 386 companies in the Biotechnology & Medical Research industry. The article highlights the company's P/E ratio of -2.28, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Form 144 Editas Medicine For: 22 July By Investing.com
This article from Investing.com is a brief announcement regarding the filing of Form 144 for Editas Medicine on July 22. It provides a quick update on a regulatory filing for the biotech company. The article contains minimal content beyond the title, indicating it's likely an automatic post about a financial filing.
Form 144 Editas Medicine For: 22 July By Investing.com
This article from Investing.com announces a Form 144 filing for Editas Medicine (EDIT) on July 22. It briefly mentions the stock's current performance (-4.97%) and does not provide further details on the filing itself, serving primarily as a notification.
Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends
Editas Medicine (EDIT) is balancing its cash usage with clinical pipeline advancements in gene-editing. The company's recent quarterly figures for fiscal 2025 showed approximately $9 million in revenue from collaborations, a substantial net loss reflecting high R&D costs, and a cash position of about $350 million indicating a multi-year operational runway. Editas Medicine continues to advance its CRISPR programs in hematology and ophthalmology, striving to hit clinical and regulatory milestones to generate confidence in its gene-editing technologies.
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts
Editas Medicine, Inc. (NASDAQ:EDIT) has received a consensus "Moderate Buy" rating from analysts, with an average target price of $5.40. The company recently reported better-than-expected EPS but missed revenue estimates, and its CEO sold a significant number of shares. Institutional investors hold approximately 71.9% of the company's stock.
Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting
Linda C. Burkly, an insider at Editas Medicine (EDIT), has filed a Form 144 indicating an intention to sell up to 5,500 shares of common stock on or after July 27, 2026. These shares are associated with Restricted Stock Unit vesting, with 11,292 shares acquired as equity compensation on July 24, 2026. This planned sale follows a previous sale of 731 shares for $1,974.50 on June 3, 2026.
Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrows
Editas Medicine (EDIT) saw its stock steady after reporting a narrowed Q1 2024 net loss of $34.3 million, down from $36.3 million year-over-year. The company's revenue declined to $5.4 million from $6.6 million, primarily due to lower collaboration income, but disciplined spending and a strong cash position of $420.9 million are expected to fund operations into 2026. Editas Medicine continues to advance its CRISPR-based pipeline, particularly EDIT-301 for sickle cell disease and beta-thalassemia, which is a key value driver.
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next?
Editas Medicine (NASDAQ:EDIT) shares recently fell below their 50-day moving average, closing at $2.88, which indicates short-term technical weakness. Analyst sentiment is mixed but leans towards "Moderate Buy" with a consensus price target of $5.40, despite recent downgrades and challenging fundamentals like missed revenue estimates. Insider selling has also been noted, with CEO Gilmore Neil O'neill selling over 15,000 shares recently.
Editas Medicine stock holds the line as pipeline work continues.
Editas Medicine remains focused on its gene-editing pipeline and Nasdaq listing, emphasizing clinical progress and regulatory milestones. As a clinical-stage company, its value is tied to development updates and balance-sheet durability, rather than immediate sales. Investors monitor funding needs and study timelines, with each update being crucial for the company's advancement through decision points.
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark
Editas Medicine, Inc. (NasdaqGS:EDIT) has been added to the Russell Small Cap Comp Growth Benchmark. The company, a genome-editing firm, is engaged in developing genomic medicines using CRISPR technology to treat various serious diseases. This inclusion highlights its growing recognition in the financial markets and follows several recent announcements regarding its preclinical data and public offerings.
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark
Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2500 Growth Benchmark. This news follows a series of recent announcements, including the company's inclusion in several other Russell benchmarks and updates on its preclinical data for EDIT-401 for hyperlipidemia. Editas Medicine, a genome-editing company, focuses on developing genomic medicines using CRISPR technology for various serious diseases.
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index
Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell Microcap Growth Benchmark Index as of June 28, 2026. This inclusion is among several other Russell index additions for the company, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000 Growth, and Russell 3000 Growth indices. The genome-editing company continues to make progress with its preclinical studies, particularly for EDIT-401, which is being developed as a potential treatment for hyperlipidemia.
